VEGFR2/CD309 Antikörper

Produktnummer ABIN967249

Produktdetails anti-VEGFR2/CD309 Antikörper

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Spezifität: VEGFR2 (Ab-951) antibody detects endogenous levels of total VEGFR2 protein.

Aufreinigung: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human VEGFR2 around the phosphorylation site of tyrosine 951 (K-D-YP-V-G).

Anwendungsinformationen

Applikationshinweise: WB: 1:500~1:1000
IHC: 1:50~1:100.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 100ug/100ul.

Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 50% glycerol

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Referenzen für anti-VEGFR2/CD309 Antikörper (ABIN967249)

Zeng, Sanyal, Mukhopadhyay et al.: "Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration ..." in: The Journal of biological chemistry, Vol. 276, Issue 35, pp. 32714-9, (2001) (PubMed).

Dougher, Terman: "Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization." in: Oncogene, Vol. 18, Issue 8, pp. 1619-27, (1999) (PubMed).

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: VEGFR2 (VEGFR2 Produkte)

Synonyme: CD309 antikoerper, FLK1 antikoerper, VEGFR antikoerper, VEGFR2 antikoerper, 6130401C07 antikoerper, Flk-1 antikoerper, Flk1 antikoerper, Krd-1 antikoerper, Ly73 antikoerper, VEGFR-2 antikoerper, sVEGFR-2 antikoerper, Vegfr-2 antikoerper, FLK-1 antikoerper, flk-1 antikoerper, vegfr-2 antikoerper, KDR antikoerper, FLK/KDR antikoerper, flk1 antikoerper, flk1b antikoerper, kdrb antikoerper, si:busm1-205d10.1 antikoerper, si:ch211-254j6.1 antikoerper, si:ch211-278f21.4 antikoerper, wu:fc31a09 antikoerper, fk52c05 antikoerper, flk antikoerper, kdr antikoerper, kdra antikoerper, vegfr2 antikoerper, vegfr4 antikoerper, vegr2 antikoerper, wu:fk52c05 antikoerper, kinase insert domain receptor antikoerper, kinase insert domain protein receptor antikoerper, vascular endothelial growth factor receptor kdr-like antikoerper, kinase insert domain receptor (a type III receptor tyrosine kinase) antikoerper, kinase insert domain receptor like antikoerper, KDR antikoerper, Kdr antikoerper, LOC100136647 antikoerper, kdr antikoerper, kdrl antikoerper

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling